Medulloblastoma subgroup-specific outcomes in irradiated children: Who are the true high-risk patients?

Neuro-Oncology

Volumn 18, Issue 2, 2016, Pages 291-297

  Ramaswamy, Vijay ^a,b   Remke, Marc ^a,b   Adamski, Jennifer ^a   Bartels, Ute ^a   Tabori, Uri ^a   Wang, Xin ^a,b   Huang, Annie ^b   Hawkins, Cynthia ^a,b   Mabbott, Donald ^a   Laperriere, Normand ^a,c   Taylor, Michael D ^a   Bouffet, Eric ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

chemotherapy; medulloblastoma; radiation; subgroups

Indexed keywords

ANTINEOPLASTIC AGENT; SONIC HEDGEHOG PROTEIN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CLINICAL PROTOCOL; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HIGH RISK PATIENT; HUMAN; MALE; MEDULLOBLASTOMA; NEUROSURGERY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; TREATMENT INDICATION; ADOLESCENT; CANCER GRADING; CEREBELLAR NEOPLASMS; CLASSIFICATION; CLINICAL TRIAL; FOLLOW UP; PATHOLOGY; PRESCHOOL CHILD; PROGNOSIS; RISK FACTOR; SKULL IRRADIATION;

ADOLESCENT; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; CRANIAL IRRADIATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEDULLOBLASTOMA; NEOPLASM GRADING; PROGNOSIS; RISK FACTORS; SURVIVAL RATE;

EID: 84960347559     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou357     Document Type: Article

References (22)

1. Ramaswamy V, Northcott PA, Taylor MD. FISH and chips: the recipe for improved prognostication and outcomes for children with medulloblastoma. Cancer genetics. 2011; 204(11):577-588.
2. Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006; 24(25):4202-4208.
3. Tarbell NJ, Friedman H, Polkinghorn WR, et al. High-risk medulloblastoma: a pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031). J Clin Oncol. 2013;31(23):2936-2941.
4. Jakacki RI, Burger PC, Zhou T, et al. Outcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: a Children's Oncology Group phase I/II study. J Clin Oncol. 2012;30(21):2648-2653.
5. Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol. 2006; 7(10):813-820.
6. Ramaswamy V, Remke M, Bouffet E, et al. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncol. 2013;14(12):1200-1207.
7. Ramaswamy V, Remke M, Shih D, et al. Duration of the pre-diagnostic interval in medulloblastoma is subgroup dependent. Pediatr Blood Cancer. 2014;61(7):1190-1194.
8. Taylor MD, Northcott PA, Korshunov A, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 2012;123(4):465-472.
9. Dubuc AM, Morrissy AS, Kloosterhof NK, et al. Subgroup-specific alternative splicing in medulloblastoma. Acta Neuropathol. 2012; 123(4):485-499.
10. Kool M, Korshunov A, Remke M, et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol. 2012;123(4): 473-484.
11. Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol. 2011; 29(11):1408-1414.
12. Remke M, Hielscher T, Korshunov A, et al. FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma. J Clin Oncol. 2011;29(29):3852-3861.
13. Remke M, Hielscher T, Northcott PA, et al. Adult medulloblastoma comprises three major molecular variants. J Clin Oncol. 2011; 29(19):2717-2723.
14. Shih DJ, Northcott PA, Remke M, et al. Cytogenetic prognostication within medulloblastoma subgroups. J ClinOncol. 2014;32(9):886-896.
15. van den Akker M, Northcott P, Taylor MD, et al. Anaplastic medulloblastoma in a child with Duchenne muscular dystrophy. J Neurosurg Pediatr. 2012;10(1):21-24.
16. Northcott PA, Shih DJ, Remke M, et al. Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. Acta Neuropathol. 2012;123(4): 615-626.
17. Zhukova N, Ramaswamy V, Remke M, et al. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol. 2013;31(23):2927-2935.
18. Tabori U, Baskin B, Shago M, et al. Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. J Clin Oncol. 2010;28(8):1345-1350.
19. Pietsch T, Schmidt R, Remke M, et al. Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort. Acta Neuropathol. 2014;128(1):137-149.
20. Schwalbe EC, Williamson D, Lindsey JC, et al. DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies. Acta Neuropathol. 2013;125(3): 359-371.
21. Kool M, Jones DT, Jager N, et al. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell. 2014;25(3):393-405.
22. Moxon-Emre I, Bouffet E, Taylor MD, et al. Impact of craniospinal dose, boost volume, and neurologic complications on intellectual outcome in patients with medulloblastoma. J Clin Oncol. 2014; 32(17):1760-1768.